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Report from the 1st Cardiovascular 
Outcome Trial (CVOT) Summit of the Diabetes 
& Cardiovascular Disease (D&CVD) EASD Study 
Group
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and Antonio Ceriello7
Abstract 
The 1st Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study 
Group was held during the annual meeting on 30 October 2015 in Munich. This summit was organized in light of 
recently published and numerous ongoing CVOTs on diabetes, which have emerged in response to the FDA and the 
EMA Guidelines. The CVOT Summit stands as a novel conference setup, with the aim of serving as a reference meet-
ing for all topics related to CVOTs in diabetes. Members of the steering committee of the D&CVD EASD Study Group 
constitute the backbone of the summit. It included presentations of key results on DPP-4 inhibitors, GLP-1-Analogues, 
SGLT-2 inhibitors, acarbose and insulins. Diabetologists’ and cardiologists’ perspective on the potential need of new 
study designs were also highlighted. Furthermore, panel discussions on the design of CVOTs on diabetes were 
included in the program. The D&CVD EASD Study Group will continue its activity. In-depth discussions and presen-
tations of new CVOTs like LEADER, will be resumed at the 2nd CVOT on diabetes of the D&CVD EASD Study Group, 
which will be held from 20–22 October 2016 in Munich (http://www.dcvd.org).
© 2016 Schnell et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Historically, the federal drug agency (FDA) Guidance for 
Industry “Diabetes mellitus: evaluating cardiovascular 
(CV) risk in new antidiabetic therapies in type 2 diabe-
tes”, issued in 2008 [1], led to the initiation of numer-
ous cardiovascular outcome trial (CVOT) studies on 
diabetes.
The aim of the Guidance for Industry is to establish the 
safety levels of newly developed antidiabetic drugs for 
type 2 diabetes treatment. To that end, sponsors should 
demonstrate that the therapy will not result in an unac-
ceptable increase in CV risk. According to FDA’s guid-
ance recommendations, to ensure that a new therapy 
does not increase CV risk to an unacceptable extent, 
the development program for novel type 2 antidiabetic 
therapies should include a prospective adjudication of 
CV events by an independent committee. These events 
should include CV mortality, myocardial infarction and 
stroke, but also can include hospitalization for acute cor-
onary syndrome, urgent revascularization procedures, 
and possibly other endpoints. Patients at higher risk of 
CV events, such as patients with relatively advanced dis-
ease, elderly patients, and patients with some degree of 
renal impairment are also recommended to be included 
in the studies.
It is important to notice that the FDA’s guidance docu-
ments do not enforce legally binding responsibilities. 
Rather, it reflects the agency’s standpoint and is to be 
viewed only as a recommendation.
The Guideline on clinical investigation of medicinal 
products in the treatment or prevention of diabetes mel-
litus of the European Medicines Agency (EMA) high-
lights the need for evaluation of various safety aspects in 
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a dataset representative of this population. It emphasizes 
that for an assessment of overall safety data in multiple 
organ systems, it is essential to, as far as possible, exclude 
that a new drug increases the risk of macrovascular com-
plications, e.g., CV disease [2].
Main body
The CVOT Summit on Diabetes of the D&CVD EASD 
Study Group was organized in light of recently published 
and numerous ongoing CVOTs on diabetes, which 
have emerged in response to the FDA and the EMA 
guidelines.
The aims of the CVOT Summit on Diabetes were:
1. Establish a sustainable platform for scientific 
exchange on CVOTs in diabetes.
2. Support in-depth discussions beyond the level of 
presentations at large-scale international congresses.
3. Create a network of key stakeholders in the field.
4. Enforce discussions among the scientific community, 
trial sponsors as well as regulatory and reimburse-
ment authorities.
5. Act as a reference group on matters related to 
CVOTs on diabetes in the future.
One of the general points of agreement was the impor-
tance of differentiating between trials with a primary 
focus in CVs safety and those that aim to a potential 
reduction of CV events.
CV safety trials, which assess CV safety of novel drugs, 
are characterized by a specific study design: They include 
high-risk diabetic patients and largely aim at glycemic 
equipoise between active and standard treatment. There-
fore studies are designed as non-inferiority comparison 
trials.
This specific design does not exclude assessment of 
potential superiority in the trials. Moreover, they also can 
generate an unprecedented amount of safety data and 
produce significant data beyond CV outcomes.
The CVOT Summit also discussed trials with a focus 
on a potential reduction of CV events.
During the 1st CVOT Summit on Diabetes several key 
questions were debated by diabetologists, cardiologists 
and initiators of CVOTs:
Do current CVOTs fulfill the needs of the scientific 
community?
It was agreed that current CVOTs are truly able to ana-
lyze CV safety of novel treatment approaches. Prior to 
EMPAREG-OUTCOME there was a feeling that given 
their nature of design FDA-driven CVOTs may be 
unable to demonstrate superiority in reducing CV risk. 
As a result, the needs of the scientific community were 
considered as being largely not fulfilled. EMPAREG-
OUTCOME changed this scenario since it showed that 
empagliflozin treatment produced a reduction of CV 
events raising the interest of the scientific community for 
this type of trials.
CVOTs should, by general agreement, address patients’ 
and physicians’ needs, as well as industry requirements 
for drug safety evaluation in patient populations, which 
typify those a physician may encounter in day-to-day 
practice.
The scientific community may also be interested in 
studies closer to the real-world setting. Real-world data 
analyses from adequately characterized data sources, 
and/or simple pragmatic interventional trials could be 
helpful in this regard.
The current lack of CVOTs with insulin (except: insu-
lin glargine (ORIGIN), insulin degludec versus insulin 
glargine (DEVOTE, ongoing)) as well as CVOTs assess-
ing metformin and sulfonylurea was also considered as a 
drawback for current treatment approaches.
If the aim of current CVOTs is to simply rule out exces-
sive mortality, the general needs of the industry can also 
be considered to be fulfilled. High investment in CVOTs, 
however, would only make sense in the future if a study 
design also enables the potential for additional benefits 
beyond demonstrating CV safety. However, the high budg-
etary efforts involved by CVTOs may only be handled by a 
very limited group of pharmaceutical companies.
Are the right kind of patients included in current CVOTs?
The fact that currently only high CV diabetic patients 
are included in CVOTs led to the discussion of whether 
CVOTs results were translatable to other patient groups.
In case of neutrality of CVOTs results or absence of 
harm of new treatment approaches, results of current 
CVOTs could be extrapolated to diabetic patients with 
a lower CV risk. However, in the event of a CV reduc-
tion, these results cannot be translated to patients with 
a lower CV risk. In this case, separate studies need to be 
performed in this concrete patient group.
On the topic of drugs affecting primarily glucose lev-
els, which may have an impact on CV outcome after 
many years, it was mentioned that including a too high 
risk population may result in a too fast accumulation of 
events. Subsequently, the interpretation of this data may 
be less conclusive.
Additionally, the need for a closer look into cancer, 
pancreatitis, kidney function and microvascular compli-
cations was emphasized.
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Is it necessary to modify CVOT design?
The following points and aspects were raised and 
discussed:
  • Primary endpoint of choice should become 
3P-MACE consisting of CV death, non-fatal MI and 
non-fatal stroke.
  • Heart failure should not necessarily be included in 
the first composite endpoint but as a secondary out-
come. However, heart failure should be more closely 
looked into.
  • In the future, novel designs may be required in larger 
populations. Including single-trial evaluation thera-
peutics of different areas.
  • Diverse blood glucose lowering drugs may be com-
pared in a single CVOT. This way a more reliable 
comparisons among therapeutic approaches will be 
possible and less patients will be on placebo.
  • In order to reduce sample size and patient number 
requierements, it is recommended the use of innova-
tive designs (e.g., RMET analyses).
  • CVOTs should focus more on the standard health 
care system and real-world settings and not be per-
formed in a rather artificial setting.
  • Proposed alternatives to CV safety trials to achieve 
robust safety data include for real-world data analy-
ses from adequately characterized sources of data, 
and/or simple pragmatic interventional trials.
  • CVOTs and their composite endpoints should be 
designed according to the mechanism of action of the 
therapeutic. Outcomes like kidney/renal function, 
cancer should also be considered in CVOTs, depend-
ing on mechanism.
  • A need for CVOTs on metformin and sulfonylurea 
was emphasized.
  • Comparison of treatment concepts, e.g., traditional 
versus innovative approaches, was highlighted.
  • Potential of CVOTs for costs reduction was dis-
cussed. Another point of the discussion was the 
need of CVOTs to fulfill the requirements of national 
reimbursement authorities.
Will guidelines change based on CVOTs results?
In the future glucose-lowering treatment strategies may 
also be classified in guidelines based on the presence/
absence of CVOTs as well as on the outcome of the 
respective CVOTs.
In view of EMPAREG-OUTCOME, empagliflozin 
could be initially recommended by guidelines for high 
CV risk diabetic patients (secondary prevention). Still the 
question whether the results reflect a class effect cannot 
be answered until additional CVOTs with SGLT2-inhib-
itors are published.
Conclusion
The 1st Cardiovascular Outcome Trial (CVOT) Summit 
of the D&CVD EASD Study Group was a highly success-
ful scientific event, which presented key results of recent 
and ongoing CVOTs in a novel as well as interactive 
multi-disciplinary setting.
The summit discussed both potentials and limitations 
of current CVOT study designs. It also produced key 
implications for future design of CVOTs on diabetes.
The D&CVD EASD Study Group will continue its activity. 
In-depth discussions and presentations of new CVOTs like 
LEADER, will be resumed at the 2nd CVOT on diabetes of 
the D&CVD EASD Study Group, which will be held from 
20–22 October 2016 in Munich (http://www.dcvd.org).
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